SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 13G/A


UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*


YD Bio Ltd
(Name of Issuer)


Ordinary Shares, par value of US$0.0001 per share
(Title of Class of Securities)


G98301107
(CUSIP Number)


02/17/2026
(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐   Rule 13d-1(b)
☐   Rule 13d-1(c)
☒   Rule 13d-1(d)




SCHEDULE 13G/A
CUSIP No.
G98301107


1 Names of Reporting Persons

Ethan Shen
2 Check the appropriate box if a member of a Group (see instructions)

☐  (a)
☐  (b)
3SEC Use Only
4 Citizenship or Place of Organization

TAIWAN
Number of Shares Beneficially Owned by Each Reporting Person With:
5 Sole Voting Power: 11,224,153.00
6 Shared Voting Power: 43,120,858.00
7 Sole Dispositive Power: 11,224,153.00
8 Shared Dispositive Power: 43,120,858.00
9 Aggregate Amount Beneficially Owned by Each Reporting Person

54,345,011.00
10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐
11 Percent of class represented by amount in row (9)

77.06 %
12 Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Numbers in Rows 5-9 consist of (i) 43,120,858 Ordinary shares held by YD Biopharma Holding Limited and (ii) 11,224,153 Ordinary shares held directly by Mr. Ethan Shen. YD Biopharma Holding Limited is a company incorporated in the Cayman Islands and Dr. Shen is the beneficial owner of all of the equity interests issued by YD Biopharma Holding Limited. Number in Row 11 is based on a total of 70,521,359 ordinary shares of the Issuer of November 17, 2025 reported in the Issuer's Rule 424(b)(3) Prospectus filed on November 17, 2025.


SCHEDULE 13G/A
CUSIP No.
G98301107


1 Names of Reporting Persons

YD Biopharma Holding Limited
2 Check the appropriate box if a member of a Group (see instructions)

☐  (a)
☐  (b)
3SEC Use Only
4 Citizenship or Place of Organization

CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5 Sole Voting Power: 0.00
6 Shared Voting Power: 43,120,858.00
7 Sole Dispositive Power: 0.00
8 Shared Dispositive Power: 43,120,858.00
9 Aggregate Amount Beneficially Owned by Each Reporting Person

43,120,858.00
10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐
11 Percent of class represented by amount in row (9)

61.15 %
12 Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Numbers in Rows 5-9 consist of 43,120,858 Ordinary shares held by YD Biopharma Holding Limited. YD Biopharma Holding Limited is a company incorporated in the Cayman Islands and Dr. Shen is the beneficial owner of all of the equity interests issued by YD Biopharma Holding Limited. Number in Row 11 is based on a total of 70,521,359 ordinary shares of the Issuer of November 17, 2025 reported in the Issuer's Rule 424(b)(3) Prospectus filed on November 17, 2025.



SCHEDULE 13G/A

Item 1. 
(a) Name of issuer:

YD Bio Ltd
(b) Address of issuer's principal executive offices:

12F., No. 3, Xingnan St., Nangang Dist., Taipei City 115001, Taiwan
Item 2. 
(a) Name of person filing:

Ethan Shen YD Biopharma Holding Limited
(b) Address or principal business office or, if none, residence:

Ethan Shen: 15 F.-5 No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist. Taipei City 115011, Taiwan YD Biopharma Holding Limited: c/o YD Biopharma Limited, 12F., No. 3, Xingnan St., Nangang Dist., Taipei City 115001, Taiwan
(c) Citizenship:

Ethan Shen - Taiwan YD Biopharma Holding Limited - Cayman Islands
(d) Title of class of securities:

Ordinary Shares, par value of US$0.0001 per share
(e) CUSIP No.:

G98301107
Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)☐   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)☐   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)☐   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)☐   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)☐   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
       please specify the type of institution:
(k)☐   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
 
Item 4.Ownership
(a) Amount beneficially owned:

See Row (9) of each cover page. Ethan Shen: 54,345,011 YD Biopharma Holding Limited: 43,120,858
(b) Percent of class:

See Row (11) of each cover page. Ethan Shen: 77.06% YD Biopharma Holding Limited: 61.15%  %
(c) Number of shares as to which the person has:
  (i) Sole power to vote or to direct the vote:

See Row (5) of each cover page. Ethan Shen: 11,224,153 YD Biopharma Holding Limited: 0

  (ii) Shared power to vote or to direct the vote:

See Row (6) of each cover page. Ethan Shen: 43,120,858 YD Biopharma Holding Limited: 43,120,858

  (iii) Sole power to dispose or to direct the disposition of:

See Row (7) of each cover page. Ethan Shen: 11,224,153 YD Biopharma Holding Limited: 0

  (iv) Shared power to dispose or to direct the disposition of:

See Row (8) of each cover page. Ethan Shen: 43,120,858 YD Biopharma Holding Limited: 43,120,858

Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
 
Not Applicable
Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
 
Not Applicable
Item 8.Identification and Classification of Members of the Group.
 
Not Applicable
Item 9.Notice of Dissolution of Group.
 
Not Applicable

Item 10.Certifications:
 
Not Applicable

    SIGNATURE 
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 
Ethan Shen
 Signature:/s/ Ethan Shen
 Name/Title:Ethan Shen
 Date:02/17/2026
 
YD Biopharma Holding Limited
 Signature:/s/ Ethan Shen
 Name/Title:Director
 Date:02/17/2026